Uveal melanoma represents approximately 5-6 % of all melanoma diagnoses, the second most common form of melanoma.
Uveal melanoma differs from cutaneous melanoma in many respects.
Clinically, nearly every patient with uveal melanoma is diagnosed with disease limited to the primary site of disease in the uveal tract (see Figure 1) . Uveal melanoma cells are thought to metastasize primarily by hematogenous spread due to a lack of lymphatic drainage in the uveal tract. 2 When uveal melanoma metastasizes, the liver is involved in up to 95 % of patients, followed by the lungs (24 %), bone (16 %) , and skin (11 %). 3 Chemotherapy, biochemotherapy, and immunotherapy regimens attempted to date have failed to show significant efficacy in metastatic uveal melanoma. 1, 4 Uveal melanomas have a different cytogenetic profile compared with cutaneous melanomas, often containing alterations in chromosomes 1, 3, 6, and 8. [5] [6] [7] [8] [9] Partial or total loss of chromosome 3 is believed to be an early genetic event and a strong predictor of metastatic disease.
Chromosome 8q copy gains, which often occur in the same tumors that have chromosome 3 loss, portend a worse prognosis. Chromosome 6p gains are nearly mutually exclusive with chromosome 3 loss and are prognostic of a non-metastatic phenotype. More recently, microarray analysis performed by several investigators has revealed two distinct profiles, 10, 11 one associated with a low risk ('class 1') and another associated with a high risk ('class 2') of metastatic disease.
In a retrospective study by Worley et al., univariate analysis showed class 2 gene expression, advanced patient age, and scleral invasion to be associated with metastasis; only class 2 gene expression was significantly associated with metastasis by multivariate analysis. 12 No one gene in the class 2 profile was predictive of metastasis.
Although mutually exclusive BRAF or NRAS mutations are found in 60-70 and 20 % of cutaneous melanomas, respectively, multiple studies using standard techniques have failed to identify these mutations in uveal melanoma tissues. [13] [14] [15] [16] [17] Using highly sensitive techniques, BRAF mutations have been identified in a subset of uveal melanomas, but appear to be present in small populations of cells within a tissue. [18] [19] [20] Likewise, KIT mutations, which are found in approximately 15-20 % of acral lentiginous and mucosal melanomas, 21 are not found in uveal melanoma tissues. 22, 23 Recent reports have demonstrated that uveal melanomas harbor activating GNAQ or GNA11 mutations in up to 85 % of cases. 24, 25 Thus it is clear that uveal melanoma differs molecularly and clinically from most other subtypes of melanoma. These differences present an opportunity and challenge for the future development of therapeutic interventions. 
Uveal Melanocyte Development

Signaling Pathways in Uveal Melanoma
The identification of activating GNAQ and GNA11 mutations and 
G-protein Alpha-q and G-protein Alpha-11 Mutations
Following the observation that activating mutations in GNAQ or GNA11 result in dermal melanocytosis in mice, van raamsdonk and Bastian investigated the GNAQ and GNA11 mutation status in subtypes of blue nevi, an intradermal melanocytic proliferative condition. 24, 28 They observed recurrent, mutually exclusive mutations in R183 and Q209
in both GNAQ and GNA11. GNAQ (Q209) mutations were present in 55 % of blue nevi, whereas GNA11 (Q209) mutations were observed in 7 %. GNAQ and GNA11 (R183) mutations were only present in 2 % of blue nevi. Recognizing that the dermally derived nevus of ota is a risk factor for uveal melanoma, this group also examined uveal melanoma tumors GNAQ or GNA11 (Q209) mutations were observed in 45 and 32 % of primary uveal melanomas, respectively. R183 mutations in either GNAQ or GNA11 were present in 6 % of primary uveal melanoma tumors. No statistically significant correlation has been observed between GNAQ or GNA11 mutation in the primary uveal melanoma tumor and clinical (overall survival, metastasis-free survival, sex, age), tissue (tumor thickness, diameter, pigmentation, or extracellular matrix patterns), cytogenetic (e.g., chromosome 3 status, 8q gain, 6p gain, 8p loss), or molecular (β-catenin, e-cadherin, cytokeratin-18) variables. 25, 30 GNA11 mutations were observed to be more prevalent in ciliochoroid tumors.
These data convincingly demonstrate that GNAQ and GNA11 are oncogenes in uveal melanoma, and targeting these genes (or protein products) or downstream signaling mediators may be a viable treatment strategy.
BAP1 Loss
It has long been postulated that the correlation between primary uveal melanoma tumors with monosomy 3 and the risk of metastatic disease may be accounted for through loss of heterozygosity of a locus on the remaining intact chromosome 3. The identification of gene aberrations that result in loss of BAP1, a previously described tumor suppressor located on chromosome 3p21.1, in a large number of primary uveal melanoma tumors with monosomy 3 provided strong evidence that BAP1 loss may be a very important mediator of metastatic disease. 31 Of tumors that were monosomy 3, and for which BAP1 mutant status could be determined, BAP1 mutations were present in 81% of cases.
BAP1 is a nuclear ubiquitin carboxy-terminal hydrolase. Previous studies have shown BAP1 to have tumor suppressor activity. 32, 33 For example, BAP1 regulated cell proliferation by e-ubiquitinating HCF-1, a cell cycle regulator. 32 A recent study shows BAP1 to be the previously uncharacterized drosophila gene calypso which is part of the polycomb group repressive de-ubiquitinase complex involved in removal of monoubiquitin from histone H2A, and ultimately stem cell pluripotency and organismal development. 34 The exact mechanism by which loss of BAP1 mediates primary uveal melanoma metastasis is currently being investigated. A further understanding of these mechanisms may provide potential pathways that can be therapeutically targeted.
Hepatocyte Growth Factor and Hepatocyte Growth Factor Receptor
Given the propensity of uveal melanoma to metastasize to the liver, many investigators have hypothesized that the liver microenvironment may contain factors that are hospitable to uveal melanoma growth.
HGF is highly produced in the liver and, when bound to the tyrosine kinase receptor MET, results in proliferation, survival, and migration in many cell types. 35 
Insulin-like Growth Factor and Insulin-like Growth Factor Receptor
Like HGF, the insulin-like growth factor-1 (IGF-1) is highly expressed in the liver and has been shown to mediate proliferation, survival, and migration in many cell types. 40 Economou et al. examined 132 primary uveal melanoma samples and showed 73 % of the tissues to have IGF1R expression. 36 Using the same analysis method used for MET analysis, they observed the intensity of IGF1R staining to be as follows: 42 % weak (<10 % staining), 22 % moderate (10-50 % staining), and 10 % strong (50-100 % staining). The relative overlap between IGF1R and MET expression was not determined. Multivariate analysis showed elevated IGF1R expression to be associated with melanoma-specific mortality.
All-Ericsson et al. examined 36 primary uveal melanoma tissues using similar criteria and observed a 94 % frequency of IGF1R expression. 41 Topcu-Yilmaz et al., limiting IGF1R positivity to membrane-only staining, observed a lower frequency of 20 % of the 40 uveal melanoma tissues examined. 39 As in the case of MET, these studies provide convincing evidence that IGF1R expression and function merit further study in uveal melanoma pathogenesis.
Using an IGF1R inhibitor, cyclolignan picropodophyllin (PPP), Girnita et al performed in vitro and xenograft experiments using uveal melanoma cell lines. Treatment with PPP diminished phospho-IGF1R levels, decreased cell viability, and inhibited cell migration. 42 In addition, tumor volume was dramatically reduced after PPP treatment in a uveal melanoma xenograft.
Notably, the majority of in vitro and all the xenograft experiments in this study were performed with uveal melanoma cell lines known to harbor a BRAF mutation. however, the number of samples was limited. 
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